ABT
Abbott LaboratoriesNYSEHealth CareMedical DevicesSnapshot 2026-05-08
As of May 8, 2026, ABT has a composite score of 16.4 and a signal label of "mild favorable." The guidance credibility score decreased to 75.0, down by 25.0 points, and the management score fell to 67.1, down by 10.1 points. These changes contribute to the overall assessment of the company's performance.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.01
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.35 → $1.28 (-5.3% / 30d). 0 raised, 6 cut, 23 covering analysts.
0 upgrades, 0 downgrades / 30d, 11 maintained. 75% of analysts rate Buy.
5 PT revisions / 30d. Avg target 22.7% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
10 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Drive organic sales growthgrowthbehind5% progress
4/16: “Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.”
Why this status
Stated in 6 of last 6 quarters. Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%. Revenue grew from $44.328 billion in 2025 to $11.164 billion in Q1 2026. Persistent statement, limited substantive delivery this quarter.
- 2.Achieve EPS growth despite acquisition impactcapital allocationmixed35% progress
4/16: “Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, including $0.20 of dilution from the acquisition.”
Why this status
Stated in 3 of last 3 quarters. Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, including $0.20 of dilution from the acquisition. EPS growth is a recurring focus, with narrow delivery so far.
- 3.Realize synergies from Exact Sciences acquisitioncapital allocationmixed35% progressprovisional
11/20: “Abbott expects at least $100 million in annual pre-tax synergies by 2028 from the acquisition.”
Why this status
Stated in 2 of last 2 quarters. Abbott expects at least $100 million in annual pre-tax synergies by 2028 from the Exact Sciences acquisition. The acquisition was completed in Q1 2026, but synergy realization is a long-term target with limited immediate impact.
Guidance track record
Last 8 quarters of EPS guidance with actuals.
Per-quarter detail
| Period | Guidance | Actual | Result |
|---|---|---|---|
| 2020-03-31 | 0.40 – 0.42 | 0.65 | beat |
| 2021-06-30 | $1.00 | $1.17 | unclassifiable |
| 2022-03-31 | $1.50 | $1.73 | unclassifiable |
| 2024-06-30 | $0.69 – $0.73 | $1.14 | beat |
| 2024-09-30 | $1.18 – $1.22 | $1.21 | inside |
| 2025-03-31 | $1.05 – $1.09 | $0.76 | miss |
| 2025-06-30 | $1.23 – $1.27 | $1.01 | miss |
| 2025-09-30 | $1.28 – $1.32 | $1.30 | inside |
Beat / inside / miss is computed from the guided range when issued; for point-estimate quarters a ±5% tolerance band around the mid is used. surprise_pct_vs_mid is unstable when guided EPS is near zero, so it is not surfaced as a headline.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 28%; 252d 24%.
Drawdown — Max 1y −38%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.66 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 60/100, drawdown 25/100, beta 66/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · guidance_credibility_scoreseverity 63
Guidance credibility fell by 25.0 points (from 100.0 to 75.0).
- score change · management_scoreseverity 25
Management fell by 10.1 points (from 77.2 to 67.1).
As of May 8, 2026, the guidance credibility score for ABT fell by 25.0 points, from 100.0 to 75.0, and the management score decreased by 10.1 points, from 77.2 to 67.1. The overall signal transitioned to "mild_favorable." The confidence level remains high at 83.6.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 75% of the last 8 guided quarters · 16.2% avg surprise
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Drive organic sales growth
GrowthNew since 2026-05-04Focus on achieving organic sales growth of 6.5% to 7.5% for 2026.
BehindStated in 6 of last 6 quarters. Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%. Revenue grew from $44.328 billion in 2025 to $11.164 billion in Q1 2026. Persistent statement, limited substantive delivery this quarter.
5%CEO/CFO:“Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.”Press releaseSource dated 2026-04-16Stated 6 of last 8 quartersFirst seen 2026-05-04Show history (6)
- 2026-Q1Press release
“Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.”
- 2025-Q4Press release
“Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.”
- 2025-Q3Press release
“Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.”
- 2025-Q2Press release
“Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%.”
- 2025-Q1Press release
“Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.”
- 2024-Q4Press release
“Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.”
- #2
Achieve EPS growth despite acquisition impact
Capital allocationNew since 2026-05-04Focus on achieving EPS growth while managing the dilution impact from the Exact Sciences acquisition.
Behind →MixedStated in 3 of last 3 quarters. Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, including $0.20 of dilution from the acquisition. EPS growth is a recurring focus, with narrow delivery so far.
35%CEO/CFO:“Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, including $0.20 of dilution from the acquisition.”Press releaseSource dated 2026-04-16Stated 3 of last 8 quartersFirst seen 2026-05-04Show history (3)
- 2026-Q1Press release
“Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.”
- 2025-Q4Press release
“Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.”
- 2025-Q3Press release
“Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range.”
- #3
Realize synergies from Exact Sciences acquisition
Capital allocationNew since 2026-05-04Focus on achieving at least $100 million in annual pre-tax synergies by 2028 from the Exact Sciences acquisition.
Behind →MixedStated in 2 of last 2 quarters. Abbott expects at least $100 million in annual pre-tax synergies by 2028 from the Exact Sciences acquisition. The acquisition was completed in Q1 2026, but synergy realization is a long-term target with limited immediate impact.
35%CEO/CFO:“Abbott expects at least $100 million in annual pre-tax synergies by 2028 from the acquisition.”Press releaseSource dated 2025-11-20Stated 2 of last 8 quartersFirst seen 2026-05-04provisionalShow history (2)
- 2026-Q1Press release
“Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market.”
- 2025-Q4Press release
“Abbott expects at least $100 million in annual pre-tax synergies by 2028 from the acquisition.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Around its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
ABT Abbott Laboratories | +16 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-16)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-16)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2712d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders. The 2026 Program was adopted by Abbott’s Board of Directors on February…
executive changeneutralscore 43 - 2026-04-1622d agoItem 2.02
Results of Operations and Financial Condition On April 16, 2026, Abbott Laboratories announced its results of operations for the first quarter 2026. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictabl…
earnings preannouncementneutralscore 39 - 2026-04-1721d agoItem 8.01
Other Events. As previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation , before the United States District Court for the Northern District of Illinois against certain of Abbott’s current and former directors and officers. On April 10, 2026, in connection with tha…
legal regulatorynegativescore 32 - 2026-03-231mo agoItem 8.01
Other Events. On March 23, 2026, Abbott Laboratories, an Illinois corporation (“Abbott”), completed the acquisition of Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among Abbott, Exact Sciences and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Abbott (“Merger Sub”). Pursuant to the terms of, and subject to the condit…
mna activitypositivescore 18 - 2026-03-092mo agoItem 1.01
Entry into a Material Definitive Agreement On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes, consisting of $1,000,000,000 aggregate principal amount of its Floating Rate Notes due 2029 (the “Floating Rate Notes”), $2,250,000,000 aggregate principal amount of its 3.700% Notes due 2029 (the “2029 Notes”), $2,500,000,000 aggregate principal amount of its 4.000% Notes due 2031 (the “2031 Notes…
capital allocationneutralscore 16
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.